OPTN - OptiNose, Inc.
IEX Last Trade
0.4031
0.003 0.620%
Share volume: 1,351
Last Updated: Thu 26 Dec 2024 07:03:52 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$0.40
0.00
0.62%
Fundamental analysis
40%
Profitability
36%
Dept financing
33%
Liquidity
74%
Performance
37%
Performance
5 Days
-8.99%
1 Month
-25.81%
3 Months
-44.00%
6 Months
-61.92%
1 Year
-69.29%
2 Year
-77.47%
Key data
Stock price
$0.40
DAY RANGE
$0.37 - $0.40
52 WEEK RANGE
$0.38 - $2.10
52 WEEK CHANGE
-$71.58
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Peter K. Miller
Region: US
Website: optinose.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: optinose.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. Onzetra Xsail, a powder EDS device, is in Phase IIIb clinical trial.
Recent news